$NBS News
Last published 6y ago
- 6y agoNBSSRNEVcinity Welcomes Seasoned Business Leader, Dr. Robin L. Smith, to Its Board of DirectorsBusiness WireSAN JOSE, Calif.--(BUSINESS WIRE)--Vcinity, Inc., a company empowering the edge and redefining cloud, today announced that Robin L. Smith, MD, MBA – a business leader, entrepreneur, medical doctor and philanthropist – joined its Board of Directors. Dr. Smith is uniquely positioned to guide and assist Vcinity during its current phase of growth and into the future.
- 12y agoFCSCNBSXONFibrocell Science Reports Second Quarter and First Half 2014 Financial and Operating ResultsBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc. (NYSE MKT:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today reported financial results for the second quarter and first half of 2014. The company will host a conference call and webcast today at 8:30 a.m. EDT.
- 12y agoFCSCNBSXONFibrocell Science Announces Plans for Process Development and Manufacturing of Genetically-modified Cell Therapy for Rare Disease, RDEBBusiness WireEXTON, Pa.--(BUSINESS WIRE)--Fibrocell Science, Inc., (NYSE MKT:FCSC), an autologous cell therapy company primarily focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, announced today that Progenitor Cell Therapy (PCT), a subsidiary of NeoStem, Inc. (NASDAQ:NBS), has been engaged by Fibrocell’s collaborator, Intrex ...
- 12y agoIMUCNBSImmunoCellular Therapeutics Expands Manufacturing Relationship with Progenitor Cell Therapy, LLC for Dendritic Cell VaccinesBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular”) (NYSE MKT:IMUC) announced the expansion of its relationship with Progenitor Cell Therapy, LLC (“PCT”), a subsidiary of NeoStem, Inc. (NASDAQ:NBS), for current good manufacturing practices (cGMP) services for ImmunoCellular’s dendritic cell-based vaccines. PCT currently manufactures ICT-121, a dendritic cell vaccine ...
- 14y agoNBSImmunoCellular Brings Second Manufacturing Site On-lineBusiness WireLOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics, Ltd. (“IMUC” or the “Company”) (OTCBB: IMUC), a clinical-stage biotechnology company that is focused on developing new immune-based products to treat and diagnose cancer, announced today that the transfer of technology from the University of Pennsylvania to a second manufacturing site is complete. Last October, IMUC entered into an arrange ...